Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137085 | 1.00 | NPC1 (0.37) | NPC1RAB9AMDM2LMNAGAA | |
| SCHEMBL3906119 | 0.90 | LMNA (0.43) | NPC1RAB9ALMNAGAAALDH1A1 | |
| SCHEMBL2683507 | 0.89 | LMNA (0.40) | NPC1RAB9AMDM2LMNAALDH1A1 | |
| SCHEMBL2683681 | 0.88 | GLA (0.43) | LMNAALDH1A1KMT2A | |
| SCHEMBL5395197 | 0.78 | KMT2A (0.41) | NPC1RAB9AMDM2LMNAGAA | |
| SCHEMBL2682798 | 0.76 | TSHR (0.42) | NPC1RAB9AMDM2LMNAALDH1A1 | |
| SCHEMBL3911172 | 0.76 | TSHR (0.42) | NPC1RAB9AMDM2LMNAALDH1A1 | |
| SCHEMBL5361146 | 0.76 | GLA (0.41) | LMNAALDH1A1KMT2A | |
| SCHEMBL2682607 | 0.76 | GLA (0.41) | LMNAALDH1A1KMT2A | |
| SCHEMBL2682454 | 0.76 | GLA (0.41) | NPC1RAB9AMDM2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-1973903-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | Speedel Experimenta AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007082907-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | NPC1 2398/4885RAB9A 874/4885MDM2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.